Previous Article | Next Article 
Infection and Immunity, July 2006, p. 4349-4353, Vol. 74, No. 7
0019-9567/06/$08.00+0 doi:10.1128/IAI.01939-05
The Animal Pathogen-Like Type III Secretion System Is Required for the Intracellular Survival of Burkholderia mallei within J774.2 Macrophages
Wilson J. Ribot and
Ricky L. Ulrich*
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011
Received 28 November 2005/
Returned for modification 19 January 2006/
Accepted 30 March 2006

ABSTRACT
Burkholderia mallei is a highly infectious gram-negative pathogen
and is the causative agent of human and animal glanders. By
generating polar mutations (disruption of
bsaQ and
bsaZ) in
the
B. mallei ATCC 23344 animal pathogen-like type III secretion
system (TTS), we demonstrate that this bacterial protein delivery
system is required for intracellular growth of
B. mallei in
J774.2 cells, formation of macrophage membrane protrusions,
actin polymerization, and phagosomal escape. These findings
suggest that TTS plays a role in the intracellular trafficking
of
B. mallei and may facilitate cell-to-cell spread via actin-based
motility.

TEXT
Burkholderia mallei is the etiologic agent of glanders and is
a gram-negative, oxidase-positive, nonmotile bacillus that is
a facultative intracellular pathogen (
3). The natural hosts
for
B. mallei are horses, donkeys, and mules (solipeds), but
other animals, including mice, hamsters, guinea pigs, monkeys,
lions, and dogs, are susceptible to this pathogen (
3,
7). Cases
of human acquired glanders in the United States are uncommon
since the implementation of quarantine strategies for imported
animals in the 21st century (
3). Both human and animal glanders
can occur in acute and chronic forms, depending on the route
of exposure. For humans, acute glanders is acquired via the
inhalational route (without treatment, death results within
days) while chronic forms of the disease occur following cutaneous
exposure to the pathogen (
3).
Various gram-negative bacterial pathogens utilize type III secretion (TTS) for toxin delivery (i.e., effector proteins) into the cytoplasm of infected cells, which in turn subverts host immunological responses to the microbe (2, 6). Recent investigations have demonstrated that the B. mallei and Burkholderia pseudomallei animal pathogen-like TTSs, which are similar to the Salmonella Inv/Spa/Prg and Shigella Ipa/Mxi/Spa TTS networks, are important for in vitro and in vivo survival of these pathogenic Burkholderia species (9-12, 14, 15). These gram-negative bacterial TTSs function to translocate bacterial effector proteins directly into the host cell, which allows bacterial pathogens to evade or alter host defenses (2, 5, 6).
We have recently shown that the B. mallei ATCC 23344 animal pathogen-like TTS is essential for full virulence in BALB/c mice and Syrian hamsters (14). In this investigation, we demonstrate that the B. mallei animal pathogen-like TTS is required for intracellular survival in J774.2 macrophages. Disruption of this TTS drastically reduced intracellular replication within J774.2 cells, prevented phagosomal escape into the host cell cytoplasm, and inhibited membrane protrusion and actin tail formation.
B. mallei strains used in this study.
The bacterial strains used in this investigation, RD01 (bsaQ::pTSV3) and RD02 (bsaZ::pTSV3), have been described by Ulrich and DeShazer (14). These B. mallei strains contain polar mutations (disrupted homologues of the Salmonella enterica serovar Typhimurium invA and spaS genes) within the animal pathogen-like TTS and are avirulent in both hamsters and BALB/c mice (14). To analyze RD01 and RD02 in vitro, a broad-host-range expression plasmid (pBHR1) encoding the green fluorescent protein (GFP) was designed as previously described (8) and mobilized into RD01 and RD02 according to the methods of DeShazer et al. (4).
Macrophage intracellular replication assays.
To determine if disrupting the B. mallei animal pathogen-like TTS affects intracellular survival and growth, J774.2 macrophages were infected with either wild-type B. mallei, RD01, or RD02 at a multiplicity of infection of 10 bacteria per macrophage in six-well plates. Cells were centrifuged for 5 min at 1,500 rpm and incubated for 1 h at 37°C with 5% CO2. Cells were washed three times with phosphate-buffered saline (PBS) and overlaid with medium containing 250 µg/ml kanamycin to prevent the growth of extracellular bacteria. At 3, 6, 12, and 18 h postinfection, macrophages were washed and lysed with 1 ml of cold sterile water containing 0.1% Triton X-100 (Sigma, St. Louis, Mo.). Cellular lysates were serially diluted 10-fold, and bacteria were enumerated on Luria-Bertani plates (Fisher Scientific, Pittsburgh, Pa.) supplemented with 4% glycerol containing 100 µg/ml trimethoprim (Sigma). All assays were performed in duplicate. As Fig. 1 depicts, the B. mallei animal pathogen-like TTS is important for the intracellular survival of B. mallei in J774.2 macrophages. At 6 h postexposure (p.e.), both RD01 and RD02 were cleared from macrophages while the number (9.8 x 104 CFU) of wild-type B. mallei organisms remained consistent (Fig. 1). At 18 h p.e., the number of wild-type B. mallei organisms reached 1.8 x 107 CFU while RD01 and RD02 remained undetected, suggesting that TTS is essential for the intracellular survival of B. mallei within J774.2 cells (Fig. 1). Interestingly, compared to B. pseudomallei macrophage intracellular growth (
105 CFU at 12 h p.e.) (11), it appears that B. mallei proliferation is more pronounced in murine macrophage-like cells (1.8 x 107 CFU by 12 h p.e.) (data not shown). Since polar mutations were generated in RD01 and RD02 TTS gene complementation studies were not performed.
Mutagenesis of the B. mallei bsaQ and bsaZ TTS genes disrupts host cell actin tail formation.
J774.2 murine macrophages were infected with wild-type
B. mallei,
RD01, or RD02 (each strain constitutively expresses GFP) as
described above, with the exception that kanamycin was replaced
with 30 µg/ml gentamicin (Sigma) to retard the growth
of extracellular bacteria (pBHR1 encodes kanamycin resistance).
After 6 h of incubation, cells were washed once with PBS and
fixed with 4% paraformaldehyde in PBS overnight at 4°C.
Cells were permeabilized with 1% Triton X-100, and filamentous
actin was stained red by overnight incubation at 4°C with
Alexa Fluor
568-phalloidin diluted to 5 U/ml in PBS (Molecular
Probes, Eugene, Oreg.). Microscopic visualization (Nikon Eclipse
TE2000-S inverted microscope equipped with a Spot-RT digital
camera; Image Systems, Columbia, Md.) of J774.2 cells infected
with wild-type
B. mallei or each TTS mutant clearly demonstrated
that the
B. mallei TTS is involved in the induction of host
cell actin polymerization (Fig.
2). Consistent with a recent
investigation (
8), Fig.
2A and D show that wild-type
B. mallei ATCC 23344 is capable of causing host cellular actin rearrangements
whereas RD01 and RD02 fail to promote actin tail formation.
These findings suggest that
B. mallei employs the Bsa TTS for
intracellular trafficking and cell-to-cell spread.
Association of B. mallei with lysosome-associated membrane glycoprotein 1 (LAMP-1).
To determine if the
B. mallei animal pathogen-like TTS is involved
in confining
B. mallei within host cell phagosomes, J774.2 macrophages
were infected as described for actin polymerization analysis
and the association of LAMP-1 with wild-type
B. mallei, RD01,
and RD02 was determined at 6 h postinfection in duplicate experiments.
B. mallei strains constitutively expressing GFP were visualized
by their green fluorescence, and LAMP-1 was detected with rat
anti-LAMP-1 (1D4B; Department of Biological Sciences, The University
of Iowa, Iowa City) and an anti-rat immunoglobulin-Alexa
568 (red; Molecular Probes) antibody. Bacteria were considered LAMP-1
associated if any region of the bacterial cell was colocalized
with LAMP-1. For quantitative analysis (percent association),
bacteria localized with LAMP-1 were determined for 500 bacilli
of wild-type
B. mallei, RD01, and RD02 and scored as LAMP-1
positive if the green fluorescent bacterial cells were surrounded
by red fluorescent membranes (data not shown) (
1). As depicted
in Fig.
3, wild-type
B. mallei was infrequently (18% of the
bacterial cells analyzed) colocalized with LAMP-1 staining.
In contrast, RD01 (97% of the cells) and RD02 (94% of the bacteria)
were heavily colocalized with LAMP-1-positive phagosomes. In
the majority of the macrophages observed, the pattern of LAMP-1
distribution differed between cells infected with wild-type
B. mallei and those infected with either RD01 or RD02 (Fig.
3). The LAMP-1 distribution in cells infected with wild-type
B. mallei was perinuclear, whereas in the RD01 and RD02 infections,
the LAMP-1 distribution was more uniformly distributed throughout
the cell (Fig.
3). A possible explanation for these differences
in LAMP-1 distribution is (i) that LAMP-1 has not yet been recruited
to the membrane or (ii) that the phagocytosed organisms, in
particular, wild-type
B. mallei, are able to escape into the
host cell cytosol (Fig.
3). The LAMP-1 staining pattern(s),
in parallel with our actin polymerization assays, suggests that
the
B. mallei bsa TTS is involved in the access of this pathogen
to the host cell cytosol, which, in turn, likely contributes
to the differences in the LAMP-1 distribution patterns within
macrophages infected with wild-type
B. mallei and each TTS mutant
(Fig.
2 and
3). These results suggest that wild-type
B. mallei is able to escape from phagosomal compartments, whereas RD01
and RD02 remain within the maturing phagolysosomes.
TTS and B. mallei phagosomal escape.
To further analyze the role of the
B. mallei animal pathogen-like
TTS, transmission electron microscopy (TEM) was employed to
determine the intracellular location of wild-type
B. mallei,
RD01, and RD02 within J774.2 cells. For TEM, macrophages were
infected with wild-type
B. mallei, RD01, or RD02 (as described
for intracellular replication assays) for 6 h and fixed at 25°C
with 2.5% glutaraldehyde in a modified Millonig buffer for 16
h. Cells were stained en bloc with 0.5% uranyl acetate in ethanol.
Samples were dehydrated in graded ethanol and propylene oxide
and embedded in Poly/Bed 812 resin (Polysciences, Inc., Warrington,
Pa.). Ultrathin sections were placed on 200-mesh nickel grids
and stained with 5% uranyl acetate and 0.2% lead citrate. Figure
4 demonstrates that wild-type
B. mallei is capable of endocytic
escape, whereas RD01 and RD02 are confined within cellular phagosomes
containing intact membranes. These findings imply that the
B. mallei animal pathogen-like TTS is required for phagosomal membrane
lysis and bacterial escape into the macrophage cytoplasm.
Several virulence determinants have recently been identified
for
B. mallei, with the most attenuated strains resulting from
disruption of genes involved in
B. mallei capsule biosynthesis
(
wcbB) (
4) and the TTS (
bsaQ and
bsaZ) (
14). In addition, we
have shown that a
B. mallei branched-chain amino acid auxotroph
was significantly attenuated in an aerosol BALB/c and hamster
model of acute glanders (
13). This investigation further shows
the importance of the
B. mallei animal pathogen-like TTS and
how this bacterial protein delivery system is required for the
intracellular replication of
B. mallei in J774.2 murine macrophage-like
cells, induction of host cell actin-based membrane protrusions,
and phagosomal escape. Additional work is needed to further
characterize the
B. mallei animal pathogen-like TTS and to identify
the secreted effector molecule(s).

ACKNOWLEDGMENTS
We thank Melanie Ulrich, David Heath, and Katheryn Kenyon for
reviewing the manuscript and Kathy Kuehl for performing the
electron microscopy.
The rat anti-LAMP-1 (1D4B) monoclonal antibody developed by J. T. August was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the Department of Biological Sciences, The University of Iowa, Iowa City. The research described herein was sponsored by NIAID interagency agreement Y1-AI-5004-01.
The opinions, interpretations, conclusions, and recommendations presented here are ours and are not necessarily endorsed by the U.S. Army.

FOOTNOTES
* Corresponding author. Mailing address: Bacteriology Division, USAMRIID, 1425 Porter St., Fort Detrick, Frederick, MD 21702. Phone: (301) 619-8332. Fax: (301) 619-8351. E-mail:
Ricky.Ulrich{at}AMEDD.ARMY.MIL.

Editor: V. J. DiRita

REFERENCES
1 - Bellaire, B. H., R. M. Roop II, and J. A. Cardelli. 2005. Opsonized virulent Brucella abortus replicates within nonacidic, endoplasmic reticulum-negative, LAMP-1-positive phagosomes in human monocytes. Infect. Immun. 73:3702-3713.[Abstract/Free Full Text]
2 - Cornelis, G. R., and F. Van Gijsegem. 2000. Assembly and function of type III secretory systems. Annu. Rev. Microbiol. 54:735-774.[CrossRef][Medline]
3 - DeShazer, D., and D. Waag. 2004. Glanders: new insights into an old disease, p. 209-237. In L. Lindler, F. Lebeda, and G. W. Korch (ed.), Biological weapons defense: infectious diseases and counterbioterrorism. The Humana Press, Inc., Totowa, N.J.
4 - DeShazer, D., D. M. Waag, D. L. Fritz, and D. E. Woods. 2001. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Microb. Pathog. 30:253-269.[CrossRef][Medline]
5 - Galan, J. E. 2001. Salmonella interactions with host cells: type III secretion at work. Annu. Rev. Cell Dev. Biol. 17:53-86.[CrossRef][Medline]
6 - Hueck, C. J. 1998. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. 62:379-433.[Abstract/Free Full Text]
7 - Miller, W. R., L. Pannell, L. Cravitz, W. A. Tanner, and T. Rosebury. 1947. Studies on certain biological characteristics of Malleomyces mallei and Malleomyces pseudomallei. J. Bacteriol. 55:115-126.
8 - Stevens, J. M., R. L. Ulrich, L. A. Taylor, M. W. Wood, D. Deshazer, M. P. Stevens, and E. E. Galyov. 2005. Actin-binding proteins from Burkholderia mallei and Burkholderia thailandensis can functionally compensate for the actin-based motility defect of a Burkholderia pseudomallei bimA mutant. J. Bacteriol. 187:7857-7862.[Abstract/Free Full Text]
9 - Stevens, M. P., A. Friebel, L. A. Taylor, M. W. Wood, P. J. Brown, W. D. Hardt, and E. E. Galyov. 2003. A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J. Bacteriol. 185:4992-4996.[Abstract/Free Full Text]
10 - Stevens, M. P., A. Haque, T. Atkins, J. Hill, M. W. Wood, A. Easton, M. Nelson, C. Underwood-Fowler, R. W. Titball, G. J. Bancroft, and E. E. Galyov. 2004. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 150:2669-2676.[Abstract/Free Full Text]
11 - Stevens, M. P., M. W. Wood, L. A. Taylor, P. Monaghan, P. Hawes, P. W. Jones, T. S. Wallis, and E. E. Galyov. 2002. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol. Microbiol. 46:649-659.[CrossRef][Medline]
12 - Suparak, S., W. Kespichayawattana, A. Haque, A. Easton, S. Damnin, G. Lertmemongkolchai, G. J. Bancroft, and S. Korbsrisate. 2005. Multinucleated giant cell formation and apoptosis in infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB. J. Bacteriol. 187:6556-6560.[Free Full Text]
13 - Ulrich, R. L., K. Amemiya, D. Waag, C. J. Roy, and D. DeShazer. 2005. Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Vaccine 23:1986-1992.[CrossRef][Medline]
14 - Ulrich, R. L., and D. DeShazer. 2004. Type III secretion: a virulence factor delivery system essential for the pathogenicity of Burkholderia mallei. Infect. Immun. 72:1150-1154.[Abstract/Free Full Text]
15 - Warawa, J., and D. E. Woods. 2005. Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol. Lett. 242:101-108.[CrossRef][Medline]
Infection and Immunity, July 2006, p. 4349-4353, Vol. 74, No. 7
0019-9567/06/$08.00+0 doi:10.1128/IAI.01939-05
This article has been cited by other articles:
-
Whitlock, G. C., Valbuena, G. A., Popov, V. L., Judy, B. M., Estes, D. M., Torres, A. G.
(2009). Burkholderia mallei cellular interactions in a respiratory cell model. J Med Microbiol
58: 554-562
[Abstract]
[Full Text]
-
Shanks, J., Burtnick, M. N., Brett, P. J., Waag, D. M., Spurgers, K. B., Ribot, W. J., Schell, M. A., Panchal, R. G., Gherardini, F. C., Wilkinson, K. D., DeShazer, D.
(2009). Burkholderia mallei tssM Encodes a Putative Deubiquitinase That Is Secreted and Expressed inside Infected RAW 264.7 Murine Macrophages. Infect. Immun.
77: 1636-1648
[Abstract]
[Full Text]
-
Lamothe, J., Valvano, M. A.
(2008). Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages. Microbiology
154: 3825-3834
[Abstract]
[Full Text]
-
Haraga, A., West, T. E., Brittnacher, M. J., Skerrett, S. J., Miller, S. I.
(2008). Burkholderia thailandensis as a Model System for the Study of the Virulence-Associated Type III Secretion System of Burkholderia pseudomallei. Infect. Immun.
76: 5402-5411
[Abstract]
[Full Text]
-
Burtnick, M. N., Brett, P. J., Nair, V., Warawa, J. M., Woods, D. E., Gherardini, F. C.
(2008). Burkholderia pseudomallei Type III Secretion System Mutants Exhibit Delayed Vacuolar Escape Phenotypes in RAW 264.7 Murine Macrophages. Infect. Immun.
76: 2991-3000
[Abstract]
[Full Text]
-
Shalom, G., Shaw, J. G., Thomas, M. S.
(2007). In vivo expression technology identifies a type VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of macrophages. Microbiology
153: 2689-2699
[Abstract]
[Full Text]
-
Fernandes, P. J., Guo, Q., Waag, D. M., Donnenberg, M. S.
(2007). The Type IV Pilin of Burkholderia mallei Is Highly Immunogenic but Fails To Protect against Lethal Aerosol Challenge in a Murine Model. Infect. Immun.
75: 3027-3032
[Abstract]
[Full Text]